Karyopharm Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 0.8798 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 19.96M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...